Biovie price to book ratio BIVI

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026: 0.9×
10-year median: 7.1×
Against its 10-year history: 16th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 68.5×
Peer median: 1.6×

Biovie's price to book ratio is 0.9× as of Oct 23, 2026.

That is below its ten-year median of 7.1×, lower than on 84% of days in the last ten years.

Over that time it ranged from 0.1× in Aug 2025 to 68.5× in Dec 2022.

The median for 3 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

median 7.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.9×	0.3×	1.6×
2025	0.4×	0.1×	2.8×
2024	2.7×	0.4×	10.1×
2023	6.3×	6.1×	30.8×
2022	39.8×	3.4×	68.5×
2021	5.6×	5.6×	44.2×
2020	16.5×	7.5×	16.5×
2019	12.2×	1.9×	21.3×
2018	2.2×	2.2×	25.5×
2017	13.1×	9.8×	23.1×
2016	16.3×	10.0×	16.6×
2015	n/m a value too high to mean anything
2014	190×	48.9×	198×

Against its peers

Companies in Drug Manufacturers - General nearest Biovie's size, closest first, today.

Company	Price to book ratio
BIVIBiovie	0.9×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Biovie

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.